Guangzhou JEEP Biotechnology: difference between revisions
Diff·revision 10 → 11·10:38, 7 Nov 2024
Difference between revision 10 and revision 11 of Guangzhou JEEP Biotechnology. 16 lines changed; the page grew by 1,812 bytes.
| Revision 10 — 05:07, 22 Oct 2024 BlindSampleBrid (talk) add the catalogue size and label it self-reported 5,372 bytes ±0 | Revision 11 — 10:38, 7 Nov 2024 ChainCustodyChad (talk) convert the product range to a table so the documentation column lines up 7,184 bytes +1,812 | ||
|---|---|---|---|
| 12 | | Official site = [https://jeepbio.com/ Visit JEEP at jeepbio.com] | 12 | | Official site = [https://jeepbio.com/ Visit JEEP at jeepbio.com] |
| 13 | }} | 13 | }} |
| + | 14 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | |
| 14 | 15 | ||
| 15 | '''Guangzhou JEEP Biotechnology Co., Ltd.''' (trading as '''JEEP'''; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.{{r|registry,selfpub}} | 16 | '''Guangzhou JEEP Biotechnology Co., Ltd.''' (trading as '''JEEP'''; jeepbio.com) is a research-peptide manufacturer based in Guangzhou, Guangdong, China, trading as JEEP Peptides, with a catalogue concentrated on incretin analogues and a substantial associated third-party testing record.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 32 | Purchaser reports describe lyophilised material in crimped glass vials with a batch certificate, insulated packaging and a cold pack.{{r|reports}} Certificate content in the submitted set has been comparatively complete for a retail supplier: purity and appearance consistently, water on most lots, and a method statement on some.{{r|usp1503}} | 33 | Purchaser reports describe lyophilised material in crimped glass vials with a batch certificate, insulated packaging and a cold pack.{{r|reports}} Certificate content in the submitted set has been comparatively complete for a retail supplier: purity and appearance consistently, water on most lots, and a method statement on some.{{r|usp1503}} |
| 33 | 34 | ||
| + | 35 | The organisation's own material describes direct manufacturing. As with every entity covered here, this wiki cannot distinguish manufacturing from repackaging or brokerage on available sources, and the claim is reproduced as a claim.{{r|selfpub}} | |
| + | 36 | ||
| + | 37 | == Product range == | |
| + | 38 | | Class | Representative listings | Documentation reported | | |
| + | 39 | |---|---|---| | |
| + | 40 | | Incretin analogues | Semaglutide, tirzepatide, retatrutide, cagrilintide | Certificate with purity, water, sometimes method | | |
| + | 41 | | Research peptides | Repair and secretagogue peptides | Certificate, purity and water | | |
| + | 42 | | SARMs and injectable oils | Bulk | Certificate, purity | | |
| + | 43 | ||
| + | 44 | == Independent testing record == | |
| + | 45 | The associated report set is substantial and, unusually, concentrated: a large number of reports across a small number of analytes.{{r|reports}} Reported [[Area percent purity|area percent]] figures have clustered tightly in the high nineties, with a narrower dispersion than for the broad-catalogue entities. | |
| + | 46 | ||
| + | 47 | Narrower dispersion across a concentrated analyte set is a more interpretable observation than a similar figure across a broad one, because fewer of the differences between reports are attributable to different chemistries and different methods.{{r|usp1503}} It remains subject to the general limitation: purchaser-submitted, purchaser-selected samples, no documented [[Chain of custody|chain of custody]], and therefore no claim about output.{{r|reports,iso17025}} | |
| + | 48 | ||
| 34 | == References == | 49 | == References == |
| 35 | {{reflist}} | 50 | {{reflist}} |
| ⋮ | ⋮ | ||
| 39 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 54 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 55 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 56 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 41 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 57 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 42 | 58 |